SEC Filing Analysis: Nuvation Bio Inc. (NUVB)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The Chief Scientific Officer conducted a pre-planned, cashless exercise of options and sold the resulting 100,000 shares for a total of $502,460, liquidating his entire direct common stock position.
• Market Impact: The transaction's small size relative to market cap and its execution under a 10b5-1 plan suggest a minimal impact on the market.

Company Information

Field	Value
Company	Nuvation Bio Inc.
Ticker Symbol	NUVB
CIK	0001811063
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	Hattersley Gary
CIK	0001521111
Title/Position	CHIEF SCIENTIFIC OFFICER
Relationship	Officer

Transaction Details

This filing reports a 'cashless exercise' where options were exercised and the acquired shares were immediately sold.

Field	Value
Form Type	4
Transaction Date	2025-10-27
Transaction Code	M (Exercise), S (Sale)
Security Type	Class A Common Stock
Shares Involved	100,000 sold
Price Per Share	$5.0246 (weighted average sale price)
Total Value	$502,460 (from sale)
Shares Owned After	0
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$502,460
% of Market Cap	0.027%
Shares Transacted	100,000
% of Shares Outstanding	0.029%
Post-Transaction Ownership	0 shares (0.0% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a company with a market capitalization of $1.84 billion, this $502k sale is financially immaterial, representing less than 0.03% of the company's value.
• Ownership Concentration: The insider now holds zero shares of common stock directly, though he still holds 298,935 stock options. The sale liquidated his entire direct common stock holding acquired in this transaction.
• Dilution Impact: The transaction involved the exercise of existing options, not a new grant, so it does not introduce new potential dilution beyond what was already disclosed.
• Transaction Significance: The sale represents a tiny fraction of the company's total shares outstanding (0.029%). Based on quantitative thresholds, the transaction's significance is low.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is too small to impact the stock price. Furthermore, its pre-scheduled nature under a 10b5-1 plan divorces it from any immediate insider sentiment, making it a non-event for the market.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is unlikely to be noticeable against the stock's average daily trading volume.
• Sentiment Indicator: Neutral to slightly Bearish. While a 10b5-1 sale is neutral, the fact that a C-suite executive sold 100% of the acquired shares to hold zero common stock is a slightly bearish signal, implying a preference for cash over equity at the current price.

Investment Insights

Positive Market Indicators

• The exercise of options itself shows some belief in the value proposition above the $1.74 strike price.

Risk Factors

• A key scientific officer liquidating his entire direct stock position could be perceived negatively, even if pre-planned.
• The insider is cashing out at a price ($5.02) significantly higher than the exercise price ($1.74), locking in profits.

Key Takeaways

1. Routine Transaction: This is a routine, pre-planned sale by an executive, likely for diversification or tax purposes.
2. Low Materiality: The transaction's value is insignificant relative to Nuvation Bio's $1.84 billion market cap.
3. 10b5-1 Plan Context: The sale was executed under a 10b5-1 plan established in June 2024, reducing its value as a real-time indicator of the insider's confidence.

Additional Context

Transaction Notes

• Special Circumstances: The sale was explicitly made pursuant to a Rule 10b5-1 trading plan. This is a critical detail that mitigates the negative signal of an insider sale.